Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05876377 · ClinicalTrials.gov registry record
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
A clinical trial of COVID-19 and SARS-CoV-2, sponsored by Pfizer.
- Active
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT05876377: Active study of COVID-19 and SARS-CoV-2, sponsored by Pfizer.
NCT05876377 is a study of COVID-19 and SARS-CoV-2 that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05876377, a study of COVID-19 and SARS-CoV-2, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: * to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. * to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.
Primary Outcome
The primary endpoint is any PCC-related diagnosis as defined by Xie et al. (2024, NEJM) that occurs between 30 and 180 days following a COVID-19 diagnosis and was not present before the COVID-19 diagnosis. The primary endpoint will also be stratified by specific organ system / disease domains (cardiovascular; coagulation and hematologic; fatigue; gastrointestinal; kidney; mental health; metabolic; musculoskeletal; neurologic; and, pulmonary). All patients are required to have a diagnosis of COVI
Conditions Studied
Interventions
- BIOLOGICAL Pfizer-BioNTech COVID-19 mRNA vaccine
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2026-09-30 |
What the registry record for NCT05876377 still lists
NCT05876377 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Pfizer-BioNTech COVID-19 mRNA vaccine is the first listed.
NCT05876377 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05876377 about?
NCT05876377 is a clinical study titled "Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data". This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: * to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. * to understand characteristics of patients who are receiving COVI...
What is the current status of trial NCT05876377?
This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2023-10-23. Estimated completion is 2026-09-30.
What conditions does trial NCT05876377 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2, Post-Acute COVID-19 Syndrome.
What interventions are being tested in trial NCT05876377?
The interventions under investigation include: Pfizer-BioNTech COVID-19 mRNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05876377?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05876377 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05876377's enrollment target sits among peer trials
1 298th of 298 the lowest of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI